Embla Medical hf (OCSE:EMBLA) Beneish M-Score: -2.53 (As of Jun. 28, 2026)


OCSE:EMBLA Embla Medical hf OCSE:EMBLA
92 GF Score
Price kr26.40
GF Value kr34.34
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Embla Medical hf Beneish M-Score?

Embla Medical hf OCSE:EMBLA 92 Beneish M-Score is -2.53 as of Jun. 28, 2026. GuruFocus rates OCSE:EMBLA with a GF Score™ of 92/100 and a GF Value™ of kr34.34 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Embla Medical hf ranks worse than 55.09% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.53 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Embla Medical hf's Beneish M-Score or its related term are showing as below:

OCSE:EMBLA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.16   Med: -2.54   Max: -2.31
Current: -2.53

During the past 13 years, the highest Beneish M-Score of Embla Medical hf was -2.31. The lowest was -3.16. And the median was -2.54.


Embla Medical hf Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Embla Medical hf's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embla Medical hf Beneish M-Score Chart

Embla Medical hf Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.53 -2.40 -2.49 -2.60 -2.57

Embla Medical hf Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.68 -2.62 -2.58 -2.57 -2.53

OCSE:EMBLA vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Embla Medical hf's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embla Medical hf Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Embla Medical hf's Beneish M-Score falls into.


OCSE:EMBLA
92GF Score
Embla Medical hf OCSE:EMBLA
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Embla Medical hf Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Embla Medical hf for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0101+0.528 * 1.0198+0.404 * 0.9852+0.892 * 1.0357+0.115 * 1.0464
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.987+4.679 * -0.024425-0.327 * 0.9668
=-2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was kr909 Mil.
Revenue was 1502.503 + 1637.278 + 1505.779 + 1503.28 = kr6,149 Mil.
Gross Profit was 924.874 + 1008.208 + 942.633 + 934.542 = kr3,810 Mil.
Total Current Assets was kr2,914 Mil.
Total Assets was kr11,050 Mil.
Property, Plant and Equipment(Net PPE) was kr1,547 Mil.
Depreciation, Depletion and Amortization(DDA) was kr399 Mil.
Selling, General, & Admin. Expense(SGA) was kr2,696 Mil.
Total Current Liabilities was kr2,412 Mil.
Long-Term Debt & Capital Lease Obligation was kr2,351 Mil.
Net Income was 93.469 + 155.658 + 164.463 + 135.252 = kr549 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = kr0 Mil.
Cash Flow from Operations was 59.83 + 321.395 + 293.926 + 143.583 = kr819 Mil.
Total Receivables was kr869 Mil.
Revenue was 1399.081 + 1600.913 + 1434.481 + 1502.698 = kr5,937 Mil.
Gross Profit was 881.496 + 1012.171 + 897.605 + 960.546 = kr3,752 Mil.
Total Current Assets was kr2,893 Mil.
Total Assets was kr10,961 Mil.
Property, Plant and Equipment(Net PPE) was kr1,434 Mil.
Depreciation, Depletion and Amortization(DDA) was kr392 Mil.
Selling, General, & Admin. Expense(SGA) was kr2,638 Mil.
Total Current Liabilities was kr1,663 Mil.
Long-Term Debt & Capital Lease Obligation was kr3,224 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(909.235 / 6148.84) / (869.195 / 5937.173)
=0.147871 / 0.146399
=1.0101

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3751.818 / 5937.173) / (3810.257 / 6148.84)
=0.63192 / 0.619671
=1.0198

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2913.646 + 1547.314) / 11049.812) / (1 - (2892.952 + 1433.55) / 10960.628)
=0.596286 / 0.605269
=0.9852

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=6148.84 / 5937.173
=1.0357

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(391.835 / (391.835 + 1433.55)) / (399.327 / (399.327 + 1547.314))
=0.214659 / 0.205136
=1.0464

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2696.281 / 6148.84) / (2637.701 / 5937.173)
=0.438502 / 0.444269
=0.987

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2351.391 + 2412.119) / 11049.812) / ((3224.291 + 1663.2) / 10960.628)
=0.431094 / 0.445913
=0.9668

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(548.842 - 0 - 818.734) / 11049.812
=-0.024425

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Embla Medical hf has a M-score of -2.53 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.53 mean?
Embla Medical hf (OCSE:EMBLA) has a Beneish M-Score of -2.53 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Embla Medical hf and its competitors. According to the industry distribution chart, Embla Medical hf ranks #422 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 55.1%.
Is Embla Medical hf's Beneish M-Score too high?
Embla Medical hf's current Beneish M-Score is -2.53. Based on the distribution chart, Embla Medical hf ranks #422 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #422 out of 766 companies for Beneish M-Score. This places Embla Medical hf in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Embla Medical hf and its competitors. Embla Medical hf's current Beneish M-Score is -2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Based on GuruFocus' analysis, Embla Medical hf (OCSE:EMBLA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.34, compared to a current price of kr26.40 — trading 23.1% below its estimated fair value. The current Beneish M-Score is -2.53. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Embla Medical hf (OCSE:EMBLA), the current Beneish M-Score is -2.53 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of kr26.40 is trading 23.1% below its estimated GF Value™ of kr34.34. GuruFocus considers Embla Medical hf to be Modestly Undervalued.

Key valuation signals for OCSE:EMBLA:

  • Beneish M-Score: -2.53
  • GF Value™: kr34.34 vs. price of kr26.40 (23.1% below fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Embla Medical hf Business Description

Other Exchanges 0FIW:UK5IQ:Germany
Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score

Get the complete analysis for OCSE:EMBLA

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.40
Price
kr34.34
GF Value